SANOFI-ADR (SNY) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SNY • US80105N1054

47.68 USD
-0.4 (-0.83%)
Last: Feb 5, 2026, 10:09 AM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to SNY. SNY was compared to 191 industry peers in the Pharmaceuticals industry. SNY has an excellent profitability rating, but there are concerns on its financial health. SNY has a decent growth rate and is not valued too expensively. SNY also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year SNY was profitable.
  • Each year in the past 5 years SNY has been profitable.
  • SNY had a positive operating cash flow in each of the past 5 years.
SNY Yearly Net Income VS EBIT VS OCF VS FCFSNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

1.2 Ratios

  • SNY has a Return On Assets of 10.63%. This is amongst the best in the industry. SNY outperforms 92.15% of its industry peers.
  • SNY has a better Return On Equity (18.84%) than 90.05% of its industry peers.
  • With an excellent Return On Invested Capital value of 13.35%, SNY belongs to the best of the industry, outperforming 93.19% of the companies in the same industry.
  • SNY had an Average Return On Invested Capital over the past 3 years of 7.41%. This is significantly below the industry average of 12.83%.
  • The 3 year average ROIC (7.41%) for SNY is below the current ROIC(13.35%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.63%
ROE 18.84%
ROIC 13.35%
ROA(3y)4.87%
ROA(5y)5.28%
ROE(3y)8.47%
ROE(5y)9.13%
ROIC(3y)7.41%
ROIC(5y)7.45%
SNY Yearly ROA, ROE, ROICSNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 20.63%, SNY belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
  • SNY's Profit Margin has declined in the last couple of years.
  • SNY has a better Operating Margin (23.61%) than 90.58% of its industry peers.
  • SNY's Operating Margin has improved in the last couple of years.
  • SNY has a Gross Margin of 72.29%. This is in the better half of the industry: SNY outperforms 79.58% of its industry peers.
  • In the last couple of years the Gross Margin of SNY has remained more or less at the same level.
Industry RankSector Rank
OM 23.61%
PM (TTM) 20.63%
GM 72.29%
OM growth 3Y-0.84%
OM growth 5Y1.78%
PM growth 3Y-3.21%
PM growth 5Y-12.66%
GM growth 3Y1.06%
GM growth 5Y1.33%
SNY Yearly Profit, Operating, Gross MarginsSNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • SNY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • SNY has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SNY has less shares outstanding
  • SNY has a worse debt/assets ratio than last year.
SNY Yearly Shares OutstandingSNY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
SNY Yearly Total Debt VS Total AssetsSNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • SNY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.18, SNY is in line with its industry, outperforming 45.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC1.73
WACC7.71%
SNY Yearly LT Debt VS Equity VS FCFSNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

2.3 Liquidity

  • SNY has a Current Ratio of 1.06. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.06, SNY is doing worse than 83.25% of the companies in the same industry.
  • SNY has a Quick Ratio of 1.06. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SNY has a worse Quick ratio (0.30) than 91.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.3
SNY Yearly Current Assets VS Current LiabilitesSNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • SNY shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.82%.
  • SNY shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.58% yearly.
  • SNY shows a small growth in Revenue. In the last year, the Revenue has grown by 5.49%.
  • Measured over the past years, SNY shows a small growth in Revenue. The Revenue has been growing by 4.57% on average per year.
EPS 1Y (TTM)1.82%
EPS 3Y-1.77%
EPS 5Y5.58%
EPS Q2Q%16.79%
Revenue 1Y (TTM)5.49%
Revenue growth 3Y0.97%
Revenue growth 5Y4.57%
Sales Q2Q%7%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.86% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.52% on average over the next years.
EPS Next Y8.1%
EPS Next 2Y6.92%
EPS Next 3Y8.79%
EPS Next 5Y8.86%
Revenue Next Year6.49%
Revenue Next 2Y6.66%
Revenue Next 3Y5.93%
Revenue Next 5Y5.52%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SNY Yearly Revenue VS EstimatesSNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B 50B
SNY Yearly EPS VS EstimatesSNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.23 indicates a reasonable valuation of SNY.
  • Compared to the rest of the industry, the Price/Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 91.10% of the companies listed in the same industry.
  • SNY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.25.
  • SNY is valuated reasonably with a Price/Forward Earnings ratio of 9.46.
  • 87.96% of the companies in the same industry are more expensive than SNY, based on the Price/Forward Earnings ratio.
  • SNY is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 10.23
Fwd PE 9.46
SNY Price Earnings VS Forward Price EarningsSNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNY Per share dataSNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • SNY's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)1.26
PEG (5Y)1.83
EPS Next 2Y6.92%
EPS Next 3Y8.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

8

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 5.08%, SNY is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.62, SNY pays a better dividend. On top of this SNY pays more dividend than 97.38% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, SNY pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.08%

5.2 History

  • The dividend of SNY has a limited annual growth rate of 4.30%.
  • SNY has paid a dividend for at least 10 years, which is a reliable track record.
  • SNY has decreased its dividend in the last 3 years.
Dividend Growth(5Y)4.3%
Div Incr Years2
Div Non Decr Years2
SNY Yearly Dividends per shareSNY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

5.3 Sustainability

  • SNY pays out 34.36% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of SNY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP34.36%
EPS Next 2Y6.92%
EPS Next 3Y8.79%
SNY Yearly Income VS Free CF VS DividendSNY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
SNY Dividend Payout.SNY Dividend Payout, showing the Payout Ratio.SNY Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SANOFI-ADR

NASDAQ:SNY (2/5/2026, 10:09:10 AM)

47.68

-0.4 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-29
Earnings (Next)04-23
Inst Owners46.74%
Inst Owner Change-1.64%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap115.16B
Revenue(TTM)46.72B
Net Income(TTM)13.80B
Analysts79.31
Price Target58.84 (23.41%)
Short Float %0.39%
Short Ratio2.87
Dividend
Industry RankSector Rank
Dividend Yield 5.08%
Yearly Dividend2.26
Dividend Growth(5Y)4.3%
DP34.36%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.79%
Min EPS beat(2)-2.29%
Max EPS beat(2)5.86%
EPS beat(4)2
Avg EPS beat(4)1.85%
Min EPS beat(4)-2.29%
Max EPS beat(4)6.02%
EPS beat(8)5
Avg EPS beat(8)3.19%
EPS beat(12)7
Avg EPS beat(12)2.67%
EPS beat(16)11
Avg EPS beat(16)3.3%
Revenue beat(2)0
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-1.3%
Max Revenue beat(2)-0.63%
Revenue beat(4)0
Avg Revenue beat(4)-1.95%
Min Revenue beat(4)-4.57%
Max Revenue beat(4)-0.63%
Revenue beat(8)2
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)8.5%
Revenue beat(16)7
Avg Revenue beat(16)20.74%
PT rev (1m)-6.05%
PT rev (3m)-6.1%
EPS NQ rev (1m)3.33%
EPS NQ rev (3m)0.87%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-1.71%
Revenue NQ rev (1m)0.41%
Revenue NQ rev (3m)0.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
Industry RankSector Rank
PE 10.23
Fwd PE 9.46
P/S 1.46
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 22.16
EV/EBITDA N/A
EPS(TTM)4.66
EY9.77%
EPS(NY)5.04
Fwd EY10.57%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS32.74
BVpS35.85
TBVpS2.15
PEG (NY)1.26
PEG (5Y)1.83
Graham Number61.31
Profitability
Industry RankSector Rank
ROA 10.63%
ROE 18.84%
ROCE 16.17%
ROIC 13.35%
ROICexc 14.69%
ROICexgc 65.49%
OM 23.61%
PM (TTM) 20.63%
GM 72.29%
FCFM N/A
ROA(3y)4.87%
ROA(5y)5.28%
ROE(3y)8.47%
ROE(5y)9.13%
ROIC(3y)7.41%
ROIC(5y)7.45%
ROICexc(3y)8.06%
ROICexc(5y)8.26%
ROICexgc(3y)31.82%
ROICexgc(5y)35.77%
ROCE(3y)8.99%
ROCE(5y)9.04%
ROICexgc growth 3Y-8.07%
ROICexgc growth 5Y1.04%
ROICexc growth 3Y-0.36%
ROICexc growth 5Y3.93%
OM growth 3Y-0.84%
OM growth 5Y1.78%
PM growth 3Y-3.21%
PM growth 5Y-12.66%
GM growth 3Y1.06%
GM growth 5Y1.33%
F-ScoreN/A
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.3
Altman-Z N/A
F-ScoreN/A
WACC7.71%
ROIC/WACC1.73
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)127.25%
Profit Quality(5y)123.49%
High Growth Momentum
Growth
EPS 1Y (TTM)1.82%
EPS 3Y-1.77%
EPS 5Y5.58%
EPS Q2Q%16.79%
EPS Next Y8.1%
EPS Next 2Y6.92%
EPS Next 3Y8.79%
EPS Next 5Y8.86%
Revenue 1Y (TTM)5.49%
Revenue growth 3Y0.97%
Revenue growth 5Y4.57%
Sales Q2Q%7%
Revenue Next Year6.49%
Revenue Next 2Y6.66%
Revenue Next 3Y5.93%
Revenue Next 5Y5.52%
EBIT growth 1Y9.12%
EBIT growth 3Y0.11%
EBIT growth 5Y6.43%
EBIT Next Year28.46%
EBIT Next 3Y13.63%
EBIT Next 5Y10.94%
FCF growth 1Y85.47%
FCF growth 3Y9.46%
FCF growth 5Y15.4%
OCF growth 1Y20.22%
OCF growth 3Y1.22%
OCF growth 5Y8.03%

SANOFI-ADR / SNY FAQ

What is the fundamental rating for SNY stock?

ChartMill assigns a fundamental rating of 5 / 10 to SNY.


Can you provide the valuation status for SANOFI-ADR?

ChartMill assigns a valuation rating of 6 / 10 to SANOFI-ADR (SNY). This can be considered as Fairly Valued.


How profitable is SANOFI-ADR (SNY) stock?

SANOFI-ADR (SNY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of SANOFI-ADR (SNY) stock?

The Price/Earnings (PE) ratio for SANOFI-ADR (SNY) is 10.23 and the Price/Book (PB) ratio is 1.33.


How sustainable is the dividend of SANOFI-ADR (SNY) stock?

The dividend rating of SANOFI-ADR (SNY) is 8 / 10 and the dividend payout ratio is 34.36%.